SCHEDULE 13G: Nantahala Capital Management Discloses 9.99% Stake in APYX Medical Corporation

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in APYX Medical Corporation's common stock as of December 31, 2024.

Summary

• Nantahala Capital Management, LLC, an investment adviser, along with its managing members Wilmot B. Harkey and Daniel Mack, collectively reported beneficial ownership of 3,493,235 shares of APYX Medical Corporation's common stock.
• This ownership represents 9.99% of the total outstanding shares of APYX Medical Corporation.
• The reported shares include 323,435 shares that can be acquired by the reporting persons within sixty days through the exercise of warrants.
• The filing was made under Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Nantahala Capital Management, LLC is a Massachusetts limited liability company, while Wilmot B. Harkey and Daniel Mack are citizens of the United States.
• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, holds the right to receive dividends or proceeds from the sale of more than five percent of the beneficially owned shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a significant stake by a reputable investment firm can signal confidence in the company, although the filing itself is purely factual and does not contain performance-related information.

Positives

• A significant stake (9.99%) by an institutional investor like Nantahala Capital Management can be viewed as a vote of confidence in APYX Medical Corporation's future prospects.
• The filing indicates the investment is for ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Negatives

• NA

Risks

• NA

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding APYX Medical Corporation's operational or financial performance.

Industry Context

This filing indicates a significant investment by an institutional fund in a medical technology company. While not providing broader industry trends, it highlights continued investor interest in the healthcare and medical device sectors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and attract new investors, potentially influencing stock price positively.
• Management: Awareness of a large institutional holder may influence management's strategic decisions and focus on shareholder value.

Key Dates

Keywords

APYX Medical Corporation, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor, Medical Devices, Healthcare